HomeBUSINESS
BUSINESS

Sumitomo Dainippon Drops Napabucasin for Stomach Cancer, but Maintains 100 Billion Yen Target
(Aug.7.2017)

Sumitomo Dainippon President Masayo Tada
Sumitomo Dainippon Pharma has discontinued the development of its hoped-to-be blockbuster cancer drug napabucasin (development code: BBI608) for the treatment of stomach cancer after its PIII setback earlier this year, but the company will stick to its peak global sales target of “at least 100 billion yen.” ...
(LOG IN FOR FULL STORY)

News Calendar